Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -24.3x - -26.9x | -25.6x |
| Selected Fwd P/E Multiple | -41.5x - -45.8x | -43.7x |
| Fair Value | $8.40 - $9.29 | $8.85 |
| Upside | -48.9% - -43.5% | -46.2% |
| Benchmarks | - | Full Ticker |
| International Stem Cell Corporation | - | OTCPK:ISCO |
| Lineage Cell Therapeutics, Inc. | - | NYSEAM:LCTX |
| Cuorips Inc. | 489,400.0% | TSE:4894 |
| Oncolys BioPharma Inc. | 458,800.0% | TSE:4588 |
| CanBas Co., Ltd. | 457,500.0% | TSE:4575 |
| SanBio Company Limited | - | OTCPK:SNBI.F |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| ISCO | LCTX | 4894 | 4588 | 4575 | SNBI.F | |||
| OTCPK:ISCO | NYSEAM:LCTX | TSE:4894 | TSE:4588 | TSE:4575 | OTCPK:SNBI.F | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 19.3% | -69.1% | -1.9% | -22.9% | 4.3% | -97.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -14.6% | -447.6% | -1764.1% | -2322.5% | -954.0% | -30394.3% | ||
| Prior Fiscal Year | -1.7% | -240.2% | -2747.8% | -3075.1% | NA | NA | ||
| Latest Fiscal Year | -2.3% | -195.9% | -368.0% | -5368.3% | NA | NA | ||
| Latest Twelve Months | -2.8% | -169.6% | -368.0% | -7858.0% | NA | NA | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 76.2x | -9.8x | -91.2x | -7.4x | NA | -50.3x | ||
| Price / LTM Sales | 0.1x | 21.6x | 295.2x | 598.9x | NA | NA | ||
| LTM P/E Ratio | -4.8x | -5.7x | -80.2x | -7.6x | -17.2x | -45.9x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -80.2x | -7.6x | -4.8x | |||||
| Historical LTM P/E Ratio | -33.8x | -14.3x | -6.7x | |||||
| Selected P/E Multiple | -24.3x | -25.6x | -26.9x | |||||
| (x) LTM Net Income | (4,270) | (4,270) | (4,270) | |||||
| (=) Equity Value | 103,773 | 109,235 | 114,697 | |||||
| (/) Shares Outstanding | 72.0 | 72.0 | 72.0 | |||||
| Implied Value Range | 1,441.00 | 1,516.84 | 1,592.68 | |||||
| FX Rate: JPY/USD | 147.7 | 147.7 | 147.7 | Market Price | ||||
| Implied Value Range (Trading Cur) | 9.76 | 10.27 | 10.78 | 16.45 | ||||
| Upside / (Downside) | -40.7% | -37.6% | -34.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ISCO | LCTX | 4894 | 4588 | 4575 | SNBI.F | |
| Value of Common Equity | 1 | 235 | 51,667 | 17,095 | 19,954 | 174,961 | |
| (/) Shares Outstanding | 8.0 | 228.4 | 8.1 | 24.8 | 19.1 | 72.0 | |
| Implied Stock Price | 0.15 | 1.03 | 6,380.00 | 688.00 | 1,044.00 | 2,429.52 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 147.69 | |
| Implied Stock Price (Trading Cur) | 0.15 | 1.03 | 6,380.00 | 688.00 | 1,044.00 | 16.45 | |
| Trading Currency | USD | USD | JPY | JPY | JPY | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 147.69 | |